PGNX Progenics Pharmaceuticals Inc.

5.46
+0.24  (+5%)
Previous Close 5.22
Open 5.25
Price To Book 5.63
Market Cap 471,605,496
Shares 86,374,633
Volume 2,289,392
Short Ratio
Av. Daily Volume 776,577

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1Q 2020.
PyL
Prostate cancer
FDA approval announced July 30, 2018.
Azedra
Pheochromocytoma
Phase 3 trial met one of two co-primary endpoints.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).
Phase 2 initiation of dosing announced June 13, 2019.
1095
Prostate Cancer

Latest News

  1. Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer
  2. Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders
  3. Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI
  4. Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan’s Latest Inaccurate Claims
  5. Velan Releases Detailed Presentation on Progenics Pharmaceuticals
  6. Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors
  7. Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims
  8. Did Changing Sentiment Drive Progenics Pharmaceuticals's (NASDAQ:PGNX) Share Price Down By 46%?
  9. Progenics to Mail Letter to Shareholders
  10. Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan
  11. Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements
  12. Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer
  13. Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved Compensation
  14. Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting
  15. Velan Responds to Progenics Pharmaceuticals' Misleading Statements
  16. Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma
  17. Progenics Pharmaceuticals Mails Letter to Shareholders
  18. Progenics Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
  19. Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting